Three studies published in leading medical journals have added to our understanding of what drives inflammatory bowel disease (IBD), the group of conditions that includes Crohn’s disease and ulcerative colitis. Together, they suggest that IBD is not one single illness, but a collection of related conditions, each shaped by different genetic and immune mechanisms. For people living with IBD, this growing understanding could eventually support earlier identification of severe disease, more tailored treatment options, and a better understanding of why some patients respond to therapy while others do not.
A genetic marker could predict severe disease
Researchers have identified a genetic marker called HLA-DRB1*01:03 that is linked to more severe forms of IBD. The discovery came from a large genetic study involving data from more than 43,000 patients. People who carry this genetic variant are more likely to need surgery or advanced treatments compared to those without it.
The study found that people who carry this variant were more likely to experience more severe IBD. Among people with Crohn’s disease, carriers were more likely to need bowel surgery and were more likely to develop perianal disease. Among people with ulcerative colitis, carriers were more likely to be admitted to hospital and more likely to need their colon removed. Across both conditions, carriers were more likely to need stronger, more advanced medicines sooner, and were somewhat more likely to stop responding to some of these treatments over time.
Currently, the course of IBD is difficult to predict. Some people experience only mild symptoms, while others develop severe, life-limiting disease. Genetic testing for this marker at diagnosis could help doctors predict which patients are more likely to develop more severe symptoms. This could allow for closer monitoring and earlier use of stronger medicines, potentially preventing hospital admissions and the need for surgery later on.
Autoantibodies to a key immune protein found in some patients
A separate study published in the New England Journal of Medicine has identified a major biological cause of IBD in a subset of patients. Researchers found that around 3.5% of people with IBD produce antibodies against their own interleukin-10 (IL-10), a protein that normally helps calm inflammation in the gut.
IL-10 acts as a brake on the immune system. When this brake is removed by these antibodies, inflammation in the gut can increase. The discovery suggests that IBD is not one disease but a collection of conditions with different underlying causes.
For patients who do not respond well to standard treatments, identifying these autoantibodies through a blood test could help explain why therapy has been ineffective. It also opens the door to more personalised treatment approaches and may guide the development of new medicines targeting this specific problem.
New genetic pathway that switches on inflammation in the gut
A third study discovered a genetic pathway that causes immune cells called macrophages to release inflammatory chemicals in the gut. The research, which focused on a gene called ETS2, found that certain genetic variations lead to an overactive immune response.
The study identified that people with a particular version of this genetic code are more likely to experience excessive inflammation when triggered. While no drugs currently exist that directly target ETS2, the researchers noted that existing medicines called MEK inhibitors could potentially interrupt this inflammatory process.
However, these inhibitors are associated with side effects, so future work will focus on delivering them in a way that affects only the gut. This research provides a clearer understanding of how inflammation starts and how it might eventually be stopped.
What this could mean for patients
Taken together, these three studies point towards a similar conclusion: IBD is not a single disease, but a group of conditions with distinct underlying causes. These discoveries represent an important step towards more personalised care for people with IBD. In the future, blood tests and genetic screening could help doctors identify who is at risk of severe disease, explain why certain treatments are not working, and guide decisions about which medicines to use.
These findings are still at a relatively early stage, and further research and clinical trials will be needed before they change day-to-day care. However, they represent a meaningful shift towards understanding the different biological causes of inflammation in IBD, rather than treating the visible symptoms alone.
References:
Zhang Q, Shakweh E, Sharip MT, Zare B, Roberts C, Wyatt NJ, et al. HLA-DRB1*01:03 in patients with inflammatory bowel disease: a genotype-phenotype association study. The Lancet Gastroenterology & Hepatology. 2026;11:660-671.
Gharahdaghi N, Yeh PJ, Ceron-Gutierrez L, et al. Interleukin-10 autoantibodies and HLA-DRB1*01:03 in inflammatory bowel disease. New England Journal of Medicine. 2026;394:2212-2222.
Stankey CT, Bourges C, Haag LM, et al. A disease-associated gene desert directs macrophage inflammation through ETS2. Nature. 2024;630:447-456.
This article is a journalistic summary for informational purposes only. It does not constitute clinical advice or a recommendation to alter treatment decisions.